More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
AUM
$412423900
P/E ratio
29.2
Dividend yield
1.2877%
Expense ratio
0.59%
Beta
0.714858
Previous close
$95.82
Today's open
$95.30
Day's range
$94.71 - $95.78
52 week range
$75.50 - $104.69
Industries
Health
NTRA
Natera Inc
5.92%
BIIB
Biogen Inc.
5.52%
5.52%
5.35%
5.21%
AMGN
Amgen Inc
5.07%
ILMN
Illumina, Inc.
5.04%
4.86%
MRNA
Moderna Inc
3.66%
EXEL
Exelixis Inc
3.21%
Which Healthcare ETF Is Best for the Long Term: State Street's XPH or Invesco's PBE?
State Street SPDR S&P Pharmaceuticals ETF provides a more diversified and lower-cost entry to the healthcare sector than its Invesco counterpart. Invesco Biotechnology & Genome ETF focuses on a narrower set of biotechnology stocks and offers a significantly higher dividend yield.
The Motley Fool • Nov 15, 2026

Better Biotech ETF: First Trust's FBT vs. Invesco's PBE
The First Trust NYSE Arca Biotechnology Index Fund has a lower expense ratio and significantly higher assets under management (AUM). The First Trust NYSE Arca Biotechnology Index Fund outperformed the Invesco fund on a 1-year total return basis and over a five-year period.
The Motley Fool • Nov 14, 2026

Why Healthcare ETFs Are Hovering Around One-Year Highs
Healthcare ETFs are hovering near 52-week highs as earnings prospects improve, clinical breakthroughs advance and GLP-1 demand expands. Explore five ETFs riding the rally.
Zacks Investment Research • Oct 23, 2026

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
The Invesco Biotechnology & Genome ETF (PBE) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Zacks Investment Research • Oct 14, 2026

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
Zacks Investment Research • Oct 13, 2026

PBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors?
PBE offers a higher dividend yield and has delivered stronger one-year total returns. RSPH offers a more affordable expense ratio and a significantly lower historical drawdown.
The Motley Fool • Sep 15, 2026

iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy?
iShares U.S. Healthcare ETF offers a more diversified portfolio and lower expense ratio than Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total return but has experienced significantly larger historical drawdowns.
The Motley Fool • Sep 9, 2026

VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style?
VanEck Pharmaceutical ETF features a lower expense ratio of 0.36% compared to 0.58% for Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total return of 47.3% but experienced a significantly deeper maximum drawdown of 34.7%.
The Motley Fool • Aug 12, 2026

XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?
State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to 0.58% for Invesco Biotechnology & Genome ETF Invesco Biotechnology & Genome ETF holds a concentrated basket of 30 biotech firms, whereas State Street Health Care Select Sector SPDR ETF provides exposure to 60 broad healthcare companies State Street Health Care Select Sector SPDR ETF has experienced a shallower maximum drawdown and lower volatility than Invesco Biotechnology & Genome ETF over the last five years
The Motley Fool • Aug 1, 2026

VHT vs. PBE: Which Health Care ETF Is the Better Buy?
The Vanguard Health Care ETF (VHT) offers broader health care exposure and has a a lower expense ratio than the Invesco Biotechnology & Genome ETF (PBE). PBE has delivered a stronger 1-year return, but has also experienced a much steeper 5-year maximum drawdown.
The Motley Fool • Jul 30, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Invesco Dynamic Biotechnology & Genome ETF commission-free¹. Build wealth for the long term using automated trading and transfers.